This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Midday Movers: Pump Up the Volume

NEW YORK (TheStreet) -- Several small-cap stocks were moving on above-average volume during Thursday's session

Labopharm (DDSS) continued to surge, rising 8 cents, or 4.3%, to $1.96 after jumping 38.2% Wednesday. Labopharm Thursday said that its wholly owned subsidiary, Labopharm Europe Limited, has completed a distribution and supply agreement with Grunenthal GmbH for its twice-daily tramadol acetaminophen formulation for a number of European countries. Labopharm will receive 3.5 million Euros on signature and up to 4 million Euros in milestone payments upon achievement of certain regulatory and product reimbursement approvals prior to the launch of the product. Volume topped 4.2 million shares, compared to the 50-day average daily volume of 489,000, according to the Nasdaq.

Tri-Valley (TIV) shares jumped 30 cents, or 10.9%, to $3.06 as volume topped 1.1 million shares, surpassing the three-month average daily volume of 390,000. There was no company-specific news released on Tri-Valley, although investor posts on Internet message boards argued that the stock was coming up against overhead resistance and could be ready for a breakout.

Astrotech (ASTC) was on the rise, climbing 39 cents, or 19.1%, to $2.43. In late September, shares surged on strong fiscal fourth-quarter earnings and had been in a steady slope downward before Thursday's session. Volume topped 970,000 shares, compared to the 50-day average daily volume of 197,000, according to the Nasdaq. Investors on Internet message boards noted the small float of only 13 million shares, which makes the stock easy to push around. Bearish investors called the stock another pump-and-dump name for daytraders.

GenCorp (GY) was on the rise with volume that was three times greater than usual after the company swung to a third-quarter profit. Shares were gaining 54 cents, or 9.7%, to $6.09 on volume that topped 1.4 million, well above the three-month average daily volume of 547,000 shares.

Cell Therapeutics (CTIC) gave back some of Wednesday's 16.3% rally as the stock was down 3 cents, or 2.7%, to $1.11 during Thursday's session. Shares have been in a recent downtrend, falling more than 20% over the last month on above-average volume. Volume topped 26.8 million shares, compared to the 50-day average daily volume of 25 million, according to the Nasdaq.

-- Written by Robert Holmes in New York.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs